Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31166760.
- Also identified by DOI 10.2214/AJR.19.21084 and PMC identifier 7469486.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>OBJECTIVE.</b> The purpose of this study is to provide a concise summary of the current experience with <sup>68</sup>Ga-labeled prostate-specific membrane antigen (PSMA)-11 imaging of prostate and nonprostate malignancies and benign conditions. <b>CONCLUSION.</b> PSMA is overexpressed in prostate cancer and in the neovasculature of many other malignancies. The relevance of PSMA as a biologic target, coupled with advances in the design, synthesis, and evaluation of PSMA-based radionuclides for imaging and therapy, is anticipated to play a major role in patient care.
Medical subject headings
- Magnetic Resonance Imaging
- Positron Emission Tomography Computed Tomography
- Positron-Emission Tomography
- Prostate-Specific Antigen
- Prostatic Neoplasms